WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a leader in the design, development, and management of complex clinical trials and patient registries for many of the world’s leading pharmaceutical and biotechnology companies, today announced the signing of multiple new contracts with an aggregate value of approximately $4.7 million. These contracts, which were signed through our European Division, are for developmental support of new clinical trials and various changes-of-scope for existing studies. More than 20 clients are represented in these contracts as well as numerous therapeutic areas including oncology, cardiovascular, central nervous system (CNS), and biologics/vaccines. Services to be provided are varied and include project management, field monitoring, data management, financial management, and quality assurance. Revenue recognition for several of these contracts began in the first quarter with the remainder beginning in the current second quarter. Revenue recognition will occur on a proportional performance basis as services are performed on each project.
